Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia.
Identifying why tumor cells suppress immune cells opens a door to reversing this sabotage and strengthening the body's natural cancer-fighting defenses in leukemia.
Tumor-induced dendritic cell deregulation suppresses T cell proliferation in ALL and correlates with inferior clinical outcomes across patient cohorts, identifying DC dysfunction as a key immune evasion axis and potential therapeutic target in acute lymphoblastic leukemia. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- translational multi-cohort study (murine model + human patient cohorts)
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Cell Rep Med
Why it surfaced
Novel DC-T cell immune evasion mechanism in ALL with translational clinical correlation published in Cell Reports Medicine. High-impact translational finding for ALL immunobiology with therapeutic targeting implications; supports investigation of DC restoration strategies in combination with immunotherapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.